This page is for patients managing diabetes, taking bisphosphonates, blood thinners or immunosuppressants who want to know whether dental implants are still an option. It covers how each condition affects eligibility, medication interactions and the medical clearance process. Most systemic health conditions do not rule out implants when properly managed.
This page provides general information about dental implant treatment and is not a substitute for individual clinical assessment.
Systemic health conditions are medical issues affecting the whole body that may influence how you heal after implant surgery. Conditions such as diabetes, osteoporosis and autoimmune disorders can affect bone metabolism, blood clotting and immune response — all of which play a role in whether a dental implant integrates successfully with the jawbone (a process called osseointegration).
Having a systemic condition does not automatically disqualify you from implant treatment. The critical factor is how well the condition is managed. A thorough pre-surgical medical assessment, often involving coordination between your dentist and GP, determines whether implant treatment can proceed safely.
Many patients who enquire about dental implant eligibility with medical conditions are not just asking whether it is possible — they want to know whether it is safe for their specific situation. That is exactly what the consultation process is designed to answer.
Ready to find out if dental implants are right for you?
Yes — patients with well-controlled diabetes can receive dental implants with outcomes comparable to non-diabetic patients. The key factor is glycaemic control, measured by HbA1c levels.
Diabetes affects implant eligibility because elevated blood sugar impairs wound healing, reduces blood flow to the gums and bone, and increases susceptibility to infection. These factors can slow osseointegration — the process by which the titanium implant fuses with the jawbone.
A systematic review of multiple meta-analyses found that implant survival in patients with controlled type 2 diabetes was comparable to non-diabetic patients, with survival rates reported between 96% and 97% at one year. However, poorly controlled diabetes was associated with increased peri-implant complications and marginal bone loss.
The Royal College of Surgeons lists uncontrolled diabetes as an exclusion criterion for NHS-funded implant treatment, reinforcing that glycaemic management is the deciding factor rather than the diagnosis itself.
Before implant surgery, your dentist will request a recent HbA1c reading from your GP. The literature uses varying thresholds for what constitutes adequate glycaemic control — some studies define well-controlled as below 7%, others below 8%. If your levels suggest poor control, treatment may be postponed until better management is achieved. Your dentist will assess your individual risk based on current clinical guidance. Perioperative antibiotic prophylaxis and chlorhexidine mouth rinse are commonly recommended to reduce infection risk in diabetic patients undergoing implant placement.
Bisphosphonates are medications prescribed for osteoporosis and certain cancers that work by inhibiting bone resorption. As a systemic health factor in implant eligibility, their main relevance is the risk of medication-related osteonecrosis of the jaw (MRONJ) — a rare but serious condition where jawbone tissue fails to heal after surgical procedures.
The risk profile differs significantly between oral and intravenous bisphosphonates. Patients receiving intravenous bisphosphonates (such as zoledronate for cancer treatment) face a substantially higher risk of MRONJ and are generally not considered suitable for elective implant surgery. The RCS and NHS Tayside guidelines list intravenous bisphosphonate therapy as an exclusion criterion for NHS-funded implant treatment.
For patients on oral bisphosphonates (such as alendronate for osteoporosis), the evidence is more nuanced. An overview of systematic reviews found that patients with a history of oral bisphosphonate use did not present a higher risk of implant failure or marginal bone loss compared to non-users. However, the surgical trauma of implant placement may increase susceptibility to osteonecrosis.
In clinical practice, the majority of MRONJ cases associated with dental procedures involve patients who have been on bisphosphonate therapy for several years, particularly via intravenous administration. When cases do arise, they are most commonly related to the duration and potency of the medication rather than the implant procedure alone.
If you take oral bisphosphonates, your implant dentist will assess the duration and type of your medication, review your medical history with your GP, and discuss the specific risks with you before deciding whether to proceed. There is currently no strong evidence that a drug holiday (temporarily stopping bisphosphonates) before implant surgery reduces MRONJ risk, as these drugs remain active in bone tissue for years.
In most cases, yes. UK dental guidelines, including the Scottish Dental Clinical Effectiveness Programme (SDCEP), advise that anticoagulant therapy generally does not need to be altered for simple implant placement. This position is also supported by the American Dental Association. Anticoagulation is one of the most common systemic health factors assessed during implant planning.
Anticoagulants (blood thinners) such as warfarin, apixaban, rivaroxaban and dabigatran are prescribed to prevent blood clots in patients with conditions such as atrial fibrillation, deep vein thrombosis or following heart valve replacement. The concern with dental surgery is the risk of prolonged bleeding.
For patients taking warfarin, an INR reading within 24 to 72 hours before surgery is standard practice. When the INR is within therapeutic range (typically 2.0 to 4.0), implant placement can proceed safely with local haemostatic measures such as sutures, oxidised cellulose and tranexamic acid mouthwash. A prospective case-control study found that implant surgery in patients continuing warfarin therapy, combined with local haemostasis, effectively prevented bleeding complications.
For patients on direct oral anticoagulants (DOACs), accumulating evidence supports continuation of medication for routine implant procedures without increased major bleeding risk. Complex cases involving bone grafting or sinus augmentation may require additional planning.
The key principle is that the risk of a thromboembolic event from stopping anticoagulation therapy far outweighs the manageable risk of surgical bleeding. Your implant dentist will coordinate with your GP or cardiologist to determine the safest approach for your specific medication regimen.
Immunosuppressant medications do not automatically prevent dental implant treatment, though they require careful assessment due to their effects on healing and infection risk.
Patients taking immunosuppressants — commonly prescribed after organ transplantation or for autoimmune conditions such as rheumatoid arthritis, Crohn’s disease or lupus — have a reduced immune response. This can slow wound healing and increase vulnerability to post-surgical infection, both of which affect osseointegration.
Despite these theoretical concerns, a systematic review assessing dental implants in organ transplant recipients (published 2021, covering 93 patients and 249 implants) reported a 100% implant survival rate over a mean follow-up of 60 months. All patients received antibiotic coverage during treatment. A separate scoping review in Clinical Oral Implants Research (2025) found overall implant survival of 85.3% to 100% across patients with various autoimmune diseases receiving immunosuppressive therapy.
Patients often ask this after reading conflicting information online — and the variation in answers is real, because the type and dose of immunosuppressant, the underlying condition being treated, and the patient’s overall health all influence the clinical decision.
If you take immunosuppressant medications, your implant dentist will liaise with your prescribing specialist to understand your current drug regimen, assess infection risk, and determine whether any timing adjustments to your medication cycle could optimise healing. Prophylactic antibiotics and a structured post-operative maintenance programme are standard for these patients.
Pre-surgical medical clearance is the process by which your dentist and GP jointly confirm that implant treatment can proceed safely given your medical history and current medications.
This process typically involves obtaining a current medical history questionnaire, requesting relevant blood tests (such as HbA1c for diabetic patients or INR for those on warfarin), reviewing your medication list for potential interactions, and contacting your GP or specialist where conditions require coordinated care.
At Deepcar Dental Care, Dr Ibraheem Ijaz conducts a comprehensive pre-surgical assessment that includes a CBCT scan (£150) to evaluate jawbone density and volume, a detailed review of your systemic health, and liaison with your medical team where required. Complex cases may be managed in collaboration with specialist Mohammed Anabtawi.
You can learn more about the full assessment and planning process in our complete guide to dental implants or learn about the technology we use at Deepcar for implant treatment.
Beyond diabetes, bisphosphonates, anticoagulants and immunosuppressants, several other systemic health conditions may influence implant candidacy. These include uncontrolled cardiovascular disease, active cancer treatment (particularly radiotherapy to the head and neck), severe blood or bone disorders, and unmanaged epilepsy.
For each condition, the question is not simply whether you have it, but whether it is well managed and whether the risks of surgery — including healing impairment and infection — are acceptable relative to the benefits. Patients who have received radiotherapy to the jaw, for example, face an elevated risk of osteonecrosis similar to the ONJ risk associated with bisphosphonates, and require specialist pre-surgical assessment. Your implant dentist evaluates each case individually, often in coordination with your medical team.
Patients concerned about whether age alone should rule out implant treatment can find specific guidance on our dedicated eligibility page. If you are concerned about recognising the signs that your implant may be failing, that topic is addressed separately.
No. You should continue your diabetes medication as prescribed. Your implant dentist needs your blood sugar to be as stable as possible during the healing period. They will request a recent HbA1c reading from your GP to confirm your glycaemic control is within an acceptable range before scheduling surgery.
Potentially, yes. Oral bisphosphonates such as alendronate carry a lower risk of osteonecrosis compared to intravenous forms. Your dentist will evaluate the duration of your bisphosphonate use and discuss the specific risks with you. Treatment decisions are made on an individual basis after a full medical review.
In many cases involving systemic health conditions, yes. A medical clearance letter from your GP helps your implant dentist understand your current health status, medication regimen and any contraindications. This is a standard part of safe treatment planning, not an indication that something is wrong.
Research suggests that well-controlled diabetes does not significantly increase implant failure rates compared to non-diabetic patients. The evidence uses varying thresholds, with some studies defining well-controlled as HbA1c below 7% and others below 8%. Poorly controlled diabetes is associated with delayed healing, increased peri-implant inflammation and greater marginal bone loss. Achieving good glycaemic control before surgery is the most important step you can take.
There is no fixed waiting period, but most clinicians prefer to wait until your immunosuppressive medication regimen is stable and your transplant team confirms your overall health is suitable for elective surgery. A systematic review covering 93 transplant patients and 249 implants reported comparable survival rates when appropriate protocols and antibiotic coverage are followed.
NHS-funded dental implants are reserved for exceptional circumstances, typically trauma, congenital conditions or cancer rehabilitation. Having a medical condition such as diabetes or taking bisphosphonates does not in itself qualify for NHS-funded implant treatment. Most patients access implants through private dental practices.
Dental implants at Deepcar Dental Care start from £2,400. The initial consultation is £100, which is redeemable against treatment. A CBCT scan is £150. Finance is available through Tabeo, with up to 18 months interest-free or up to 60 months at 10.9% APR representative. Learn more about spreading the cost of dental implants with monthly payments.
If you have worked through the questions on this page, you likely have a clearer picture of whether dental implants may be suitable for you despite a medical condition. The next step is a conversation with a clinician who can assess your specific situation. Book your consultation at Deepcar Dental Care — call 0114 288 2121 or book online.
Dr Ibraheem Ijaz (GDC 301711) assesses every patient’s periodontal status as part of the implant consultation at Deepcar Dental Care, Sheffield. Dr Ijaz will map out every stage — from gum stabilisation through to final restoration — so you know exactly what to expect before committing.
Return to our main dental implants page to explore the full range of implant treatments and information at Deepcar Dental Care.